Consensus Prime Medicine, Inc.

Equities

PRME

US74168J1016

Real-time Estimate Cboe BZX Other stock markets 13:51:37 2024-05-17 EDT			5-day change	1st Jan Change
7.16 ^USD	+1.70%		+27.45%	-19.30%

12:25pm	North American Morning Briefing : The "Everything -2-	DJ
05-16	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target	MT

Evolution of the average Target Price on Prime Medicine, Inc.

Price target over the last 5 years

History of analyst recommendation changes

def58364fd6f74cdb0e95c109d8.ejv_A71At4gxEgvMnhez76cr77K33wvs5fLpnfzaf-I.FHaGdc4Ex91QJkK68mXgns9n2MffiGq0h4Gh0aiWPaA2brhvhTHx62hNeA~3f5644e6f9ac86adbf609edb6f8f3e01

Analyst Recommendations on Prime Medicine, Inc.

Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target	05-16	MT
JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating	05-13	MT
Chardan Initiates Prime Medicine With Buy Rating, Price Target is $17	04-22	MT
Chardan Initiates Prime Medicine at Buy With $17 Price Target	04-22	MT
Wedbush Initiates Prime Medicine With Outperform Rating, $12 PT; Notes Positive Long-Term Outlook on Gene Editing Platform	04-03	MT
Guggenheim Cuts Prime Medicine's Price Target to $20 From $24, Maintains Buy Rating	03-05	MT
Morgan Stanley Cuts Price Target on Prime Medicine to $12 From $18, Keeps Equalweight Rating	12-12	MT
BMO Capital Starts Prime Medicine at Outperform, $19 Price Target	23-10-09	MT
Jones Trading Starts Prime Medicine at Buy With $20 Price Target	23-09-06	MT
Morgan Stanley Adjusts Price Target on Prime Medicine to $19 From $21, Keeps Equalweight Rating	23-08-14	MT
Guggenheim Starts Prime Medicine at Buy With $24 Price Target	23-07-31	MT
Stifel Initiates Prime Medicine at Hold With $18 Price Target	23-04-18	MT
Morgan Stanley Adjusts Price Target on Prime Medicine to $21 From $23, Maintains Equal-Weight Rating	23-01-24	MT
Goldman Sachs Starts Prime Medicine at Neutral With $22 Price Target	22-11-14	MT
JPMorgan Starts Prime Medicine at Overweight With $27 Price Target	22-11-14	MT
Jefferies Starts Prime Medicine at Buy With $25 Price Target	22-11-14	MT
Morgan Stanley Starts Prime Medicine at Equalweight With $23 Price Target	22-11-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.04 USD

Average target price

14.6 USD

Spread / Average Target

+107.39%

High Price Target

20 USD

Spread / Highest target

+184.09%

Low Price Target

9 USD

Spread / Lowest Target

+27.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Prime Medicine, Inc.

Citigroup
JPMorgan Chase
Chardan Research
Wedbush
Guggenheim
Morgan Stanley
BMO Capital
JonesTrading Institutional Services
Stifel Nicolaus
Jefferies & Co.
Goldman Sachs

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar